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Abstract Rho GTPases participate in various important
signaling pathways and have been implicated in myogenic
differentiation. Here the first evidence is provided that in
C2C12 myoblasts sphingosine 1-phosphate (SPP) rapidly and
transiently induced membrane association of RhoA in a pertussis
toxin-insensitive manner. The bioactive lipid preferentially
relocalized the GTPase to Golgi-enriched membrane. Transloca-
tion of RhoA was abolished by inhibition or down-regulation of
protein kinase C (PKC). Notably, treatment with Go«6976, an
inhibitor of conventional PKCs, which selectively blocked PKCK
in these cells, prevented SPP-induced RhoA translocation.
Conversely rottlerin, a selective inhibitor of PKCN, was without
effect, demonstrating that SPP signaling to RhoA involves
PKCK but not PKCN activation. This novel functional relation-
ship between the two proteins may have a role in SPP-mediated
regulation of downstream effectors. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The Rho subfamily of small GTP binding proteins, which
includes Rho, Rac and Cdc42, has been implicated in the
regulation of a number of biological processes including cell
motility, cell adhesion, cytokinesis, cell morphology and cell
growth [1,2]. Rho GTPases act as molecular switches cycling
between an inactive GDP-bound state and an active GTP-
bound state. The two alternative protein states also di¡er in
intracellular localization: upon activation the cytosolic GDP-
bound form is recruited to the membrane. The major function
of Rho GTPases is to regulate the assembly and the organi-
zation of the actin cytoskeleton [3]. Recent studies have shown
the existence of a large number of upstream activators and
regulators of Rho proteins as well as the occurrence of a
variety of e¡ectors or target molecules able to interact with
active Rho proteins to initiate a downstream response [3,4],
indicating a high level of complexity in the regulation of Rho
protein function.
Several lines of experimental evidence support a role for
Rho GTPases in the di¡erentiation of skeletal muscle. Dom-
inant negative forms of Rho family proteins and RhoGDI, a
GDP dissociation inhibitor, suppressed transcription of
muscle-speci¢c basic helix-loop-helix transcription factors
such as myogenin in C2C12 muscle cells [5]. Moreover, in
mouse myoblasts RhoA, but not Rac or Cdc42, appears to
be required for the expression of MyoD, another key operator
in skeletal muscle di¡erentiation [6]. Finally, Rac1 appears to
play a critical role in primary avian myoblast di¡erentiation
[7].
Sphingosine 1-phosphate (SPP), a serum-borne bioactive
lysophospholipid, evokes multiple cellular responses, at least
in part, through the interaction with di¡erent speci¢c G pro-
tein-coupled receptors belonging to the endothelial di¡erentia-
tion gene (Edg) family [8]. In a number of circumstances bio-
logical actions elicited by the bioactive lipid rely on
cytoskeletal rearrangement and Rho protein activation [9].
Consistent with this, a role for RhoA has been established
in SPP-induced invasion of T-cell lymphoma [10], neurite re-
traction in neuroblastoma cells [11] and ¢bronectin matrix
assembly [12]. Moreover, Rho and Rac have been shown to
be coupled to the vascular endothelial cell adherens junction
assembly induced by SPP [13]. However, the signaling path-
way responsible for SPP-induced Rho GTPase activation has
not been clari¢ed so far. In a previous study Edg1, Edg3 and
Edg5 receptors were detected in C2C12 myoblasts and SPP
was demonstrated to be capable of inducing protein kinase C
(PKC) and phospholipase D signaling pathways [14], but no
information is presently available about the possible regula-
tion of Rho GTPases by the bioactive lipid in skeletal muscle.
Here we report that in C2C12 myoblasts SPP was capable
of activating rapidly RhoA and that inhibition of PKCK but
not PKCN impaired RhoA activation, implying a permissive
role for PKCK in the signaling of SPP to RhoA.
2. Materials and methods
2.1. Materials
Mouse skeletal muscle C2C12 cells were from the American Type
Culture Collection (ATCC, Manassas, VA, USA). Biochemicals, cell
culture reagents and monoclonal antibodies against Golgi p58 were
from Sigma (St. Louis, MO, USA). SPP and Go«6976 were from
Calbiochem (San Diego, CA, USA); pertussis toxin (PTx) was from
List Biological Laboratories (Campbell, CA, USA). Rottlerin was
from Alexis Corporation (San Diego, CA, USA). I-block was from
Tropix (Bedford, MA, USA). Mouse monoclonal antibodies against
RhoA, Rac1 and caveolin-1, polyclonal antibodies against Cdc42 and
secondary antibodies (horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit immunoglobulin G1) were from Santa Cruz
(Santa Cruz, CA, USA). Mouse monoclonal anti-PKCK and anti-
PKCN antibodies were from Transduction Laboratories (Lexington,
KY, USA). Rabbit polyclonal anti-Rab5 and anti-calnexin antibodies
were purchased from Stressgene Biotech (Victoria, BC, Canada).
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2.2. Muscle cell culture
C2C12 mouse myoblasts were grown in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) supplemented with 10% fetal bovine serum, as
previously described [15]. The cells were seeded into 100 mm diameter
dishes and when 90% con£uent they were shifted to DMEM without
serum containing 1 mg/ml bovine serum albumin for 24 h and then
utilized for the experiments.
2.3. Cellular fractionation
Medium of control and agonist-treated C2C12 cells was removed
and the cells were washed twice with ice-cold phosphate-bu¡ered sa-
line, scraped, and collected by centrifugation (1000Ug). The cells were
dispersed in a bu¡er solution containing 10 mM HEPES, pH 7.4,
1 mM EGTA, 1 mM EDTA, 250 mM sucrose, 5 mM NaN3, and
protease inhibitors (1 mM 4-(2-aminoethyl)benzenesulfonyl £uoride,
0.3 WM aprotinin, 10 Wg/ml leupeptin and 10 Wg/ml pepstatin) and
disrupted in a Dounce homogenizer (120 strokes). Lysates were cen-
trifuged (7 min, 500Ug) and the resulting supernatant was centrifuged
again at 200 000Ug for 1 h to separate cytosolic and total particulate
fractions. Protein content was quanti¢ed according to the Coomassie
blue procedure using a commercially available kit (Bio-Rad).
2.4. Sucrose density fractionation
Control and SPP-treated C2C12 cells, collected as described above,
were dispersed in a bu¡er solution containing 10 mM HEPES, pH 7.4,
250 mM sucrose, 1 mM MgCl2, 1 mM dithiothreitol, 5 mM NaN3,
and protease inhibitors (1 mM 4-(2-aminoethyl)benzenesulfonyl £uo-
ride, 0.3 WM aprotinin, 10 Wg/ml leupeptin and 10 Wg/ml pepstatin)
and disrupted in a Dounce homogenizer (120 strokes). Lysates were
spun (7 min, 500Ug) and the resulting supernatant was centrifuged
for 30 min at 200 000Ug to prepare Golgi. The pellet was gently
dispersed in the same bu¡er containing 1.4 M sucrose. A sample
(800 Wl) was transferred to the bottom of a centrifuge tube that con-
tained layers of 0.25, 0.85, 1.15 and 1.4 M sucrose in the same bu¡er
without sucrose and protease inhibitors. After centrifugation (19 h,
200 000Ug, Beckman SW50 rotor) the subcellular fractions localized
at the interfaces of the sucrose layers were collected and used for
Western analysis.
2.5. Western blot analysis
Proteins (30 Wg) from cellular fractions of unstimulated and ago-
nist-stimulated myoblasts were separated by SDS^PAGE. Proteins
were electrotransferred to nitrocellulose membranes, which were in-
cubated overnight in Tris-bu¡ered saline containing 0.1% Tween-20
(TTBS) and 0.5% I-block. Hybridization for 1 h at room temperature
with primary antibodies was followed by washing with TTBS and
incubation with peroxidase-conjugated goat anti-mouse or anti-rabbit
IgG1. Proteins were detected by enhanced chemiluminescence (ECL,
Amersham Pharmacia Biotech).
2.6. Presentation of data
A blot representative of at least three similar experiments is pre-
sented. To test the statistical signi¢cance band intensities were mea-
sured using NIH Image and the control corresponding to no addition
and time zero was set at 100% in each individual experiment.
3. Results
3.1. E¡ect of SPP on Rho GTPase translocation
To evaluate the possible activation of monomeric G pro-
teins by SPP, the subcellular redistribution of RhoA, Cdc42
and Rac1 induced by the agonist was examined. To this end
translocation from cytosol to membranes, known to be
coupled with protein activation by replacement of bound
GDP with GTP, was monitored. Incubation of cells for 30 s
Fig. 1. E¡ect of SPP on Rho GTPase membrane translocation. A: Serum-starved con£uent myoblasts were incubated without or with the indi-
cated concentration of SPP for 30 s or with 1 WM SPP for the indicated time. Samples (30 Wg protein) from cytosol (Cyt) or membrane frac-
tion (M) of control or SPP-stimulated cells were separated by SDS^PAGE in 14% gel and transferred to nitrocellulose as described in Section
2. A blot representative of three similar experiments is presented. B: Con£uent myoblasts were incubated in serum-free medium without or
with 200 ng/ml PTx for 16 h before stimulation with 1 WM SPP or 5 WM lysophosphatidic acid for 30 s. Samples (30 Wg protein) from mem-
brane fraction were electrophoresed and transferred to nitrocellulose. A blot representative of three similar experiments is presented and band
intensity is reported as percentage (mean þ S.D.) relative to control (no addition, 100%).
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with SPP resulted in a transient translocation of RhoA from
cytosol to membrane fraction which was concentration-depen-
dent (Fig. 1A). A signi¢cant increase in membrane-associated
RhoA was observed with 50 nM SPP, the maximal e¡ect
being reached with 1 WM. RhoA translocation was maximal
within 1 min. Conversely, no increase in membrane associa-
tion of Rac1 or Cdc42 was observed at 30 s (Fig. 1A). Alto-
gether, these ¢ndings indicated that RhoA, but not other
monomeric G proteins, was involved in early SPP-induced
signaling pathways. In addition, at 2.5 min a signi¢cant asso-
ciation of Rac1 with the membrane fraction could be detected
(data not shown), suggesting a possible involvement of this
protein in later SPP-mediated events. Given that the various
SPP-speci¢c Edg receptors are coupled to multiple heterotri-
meric G proteins, the possible involvement of Gi/Go in the
signaling pathway leading to RhoA activation was investi-
gated. In pilot experiments designed to optimize the modi¢-
cation of Gi/Go proteins by PTx treatment (200 ng/ml, 16 h),
the cells were incubated with [32P]nicotinamide adenine dinu-
cleotide and activated toxin. In membranes from cells treated
with toxin, no further labeling of Gi/Go was observed (data
not shown). Membrane translocation of RhoA induced by the
bioactive lipid was not inhibited in myoblasts treated with
PTx. In contrast, the toxin completely prevented RhoA mem-
brane translocation induced by lysophosphatidic acid, a lipid
molecule similar in structure to SPP (Fig. 1B).
3.2. Inhibition of PKCK impairs SPP-induced RhoA
translocation
In a previous study we demonstrated that SPP rapidly acti-
vated PKCK, PKCN and PKCV [14]. To investigate whether
the PKC signaling pathway may interfere with SPP-induced
RhoA activation, PKC activity was inhibited by prolonged
exposure to phorbol 12-myristate 13-acetate (800 nM, 20 h)
or by treatment with GF109203X (10 WM), an inhibitor of all
PKCs. As shown in Fig. 2A, SPP-induced RhoA translocation
was abolished in PKC-down-regulated myoblasts as well as
when all PKC isoforms were blocked. To investigate this
point deeply, similar experiments were performed in the pres-
ence of Go«6976 (0.5 WM), a selective inhibitor of conventional
PKCs, or rottlerin (5 WM), a speci¢c inhibitor of the novel
isoform PKCN. As expected, the two inhibitors blocked mem-
brane recruitment of PKCK or PKCN, respectively, promoted
by SPP in C2C12 cells (Fig. 2B). Remarkably, Go«6976 pre-
vented the SPP-induced increase in membrane-associated
RhoA whereas rottlerin was ine⁄cacious (Fig. 2A).
Fig. 2. E¡ect of inhibition of PKC on SPP-induced RhoA (A) and PKCK or PKCN (B) membrane translocation. Upper panel: Serum-starved
myoblasts were incubated with vehicle (0.05% dimethylsulfoxide), 10 WM GF109203X, 0.5 WM Go«6976 or 5 WM rottlerin for 30 min or incu-
bated for 20 h with 800 nM phorbol 12-myristate 13-acetate to down-regulate PKC prior to stimulation with 1 WM SPP for 30 s. Proteins (25
Wg) from membrane fraction were separated by SDS^PAGE and transferred to nitrocellulose. Blot is representative of those from at least three
similar experiments. Lower panel: Densitometric analysis. Band intensity is reported as percentage (mean þ S.D.) relative to control (no addi-
tion, 100%). *Statistically signi¢cant (P6 0.01).
Fig. 3. Subcellular distribution of SPP-activated RhoA and PKCK.
Cell lysates were fractionated as described in Section 2. Samples (25
Wg) of membrane fractions (CELM; fractions 3^4), Golgi-enriched
membranes (G; fractions 13^14), endoplasmic reticulum (ER; frac-
tions 16^17), endosomes/plasma membranes (C/PM; fractions 19^
20) were separated by SDS^PAGE, transferred to nitrocellulose and
analyzed for the presence of marker proteins. Membrane fractions
prepared from myoblasts incubated without or with 1 WM SPP for
30 s and positive for the speci¢c compartment marker were collected
and analyzed for the expression of RhoA and PKCK. A blot repre-
sentative of three similar experiments is presented.
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3.3. Subcellular distribution of SPP-activated RhoA and PKCK
Next the subcellular membrane distribution of RhoA and
PKCK in control and SPP-stimulated C2C12 cells was exam-
ined. For this purpose cell lysates were fractionated on a dis-
continuous sucrose density gradient and fractions analyzed
for the presence of speci¢c subcellular markers: fractions 3^
4 were identi¢ed as caveolin-enriched light membrane
(CELM) fractions, by the detection of caveolin-1; fractions
13^14 corresponded to Golgi-enriched membranes based on
the presence of p58; fractions 16^17, which were enriched in
calnexin, preferentially contained membranes of endoplasmic
reticulum; and fractions 19^20 corresponded to endosomes/
plasma membranes based on the enrichment in Rab5. As
shown in Fig. 3, RhoA was detectable to a similar extent in
all examined subcellular compartments, except for the caveo-
lar microdomains. Following SPP stimulation activated RhoA
preferentially associated with Golgi while a slight increase
could also be detected in endosomes/plasma membranes. In-
stead, PKCK was ubiquitous in the examined fractions and
was highly enriched in CELMs; in stimulated cells the kinase
translocated in all compartments except endoplasmic reticu-
lum.
4. Discussion
Evidence is emerging that RhoA GTPase plays a critical
role in the signaling of SPP, although so far its involvement
in the transduction machinery activated by the bioactive lipid
has been demonstrated almost exclusively on the basis of
Clostridium botulinum C3 exoenzyme sensitivity of biological
processes which require active RhoA [12,13,16,17]. In the
present report a rapid and transient translocation of RhoA
is shown to occur following stimulation of C2C12 myoblasts
with SPP. Interestingly, a detailed analysis of subcellular dis-
tribution revealed that RhoA was relocalized by SPP mainly
to Golgi-enriched membranes, suggesting that agonist-acti-
vated protein acts in highly de¢ned subcellular compartments.
Interestingly, the short-term translocation of RhoA was not
accompanied by membrane recruitment of other Rho
GTPases, although Rac1 was activated at a more prolonged
time of agonist treatment. A hierarchical cascade linking Rho,
Rac and Cdc42 was initially described in cultured ¢broblasts
[2] and a role for Rac in the activation of Rho has been
proposed [18]. Here the occurrence of such a kind of regula-
tion can be ruled out taking into account the more rapid time
course of RhoA activation in comparison with that of Rac1.
In agreement with other studies [13,16] SPP-induced RhoA
translocation was insensitive to PTx treatment, suggesting
that the signaling pathway involves heterotrimeric G12=13
and/or Gq protein. However, given that Edg3 and Edg5
[16,19] as well as Edg1 [20] have been implicated in Rho-de-
pendent pathways and all these receptor subtypes are ex-
pressed in C2C12 myoblasts [14] it appears di⁄cult to attrib-
ute the observed increased RhoA translocation to one or more
Edgs. The here reported activation of RhoA by SPP, in view
of the importance of RhoA functioning for myogenic di¡er-
entiation [5^7], suggests that the bioactive lipid is responsible
for key morphogenetic changes in these cells.
A major ¢nding of the present study is represented by the
evidence for a functional relationship between a speci¢c PKC
isoform and RhoA translocation in SPP-stimulated cells; in-
deed, catalytic activity of conventional PKCs but not PKCN
was required for the ligand-induced membrane association of
the GTPase protein. Given that in C2C12 myoblasts [14] and
in rat muscle [21] PKCL was undetectable, the inhibition of
conventional PKCs obtained in the presence of Go«6976 im-
plied a selective blocking of PKCK. Therefore on this basis it
is possible to ascribe speci¢cally to PKCK a permissive role in
SPP signaling leading to RhoA activation. The mechanism by
which PKCK interferes with the agonist-mediated membrane
recruitment of RhoA is at present unknown, however several
hypotheses can be advanced. One theoretical possibility is
represented by a direct interrelationship between these two
molecules. Evidence for this stems from studies which showed
that Pkc1, the yeast homologue of classical mammalian PKC,
coimmunoprecipitated with Rho1, corresponding to RhoA in
mammalian systems [22]. The broad subcellular distribution
of PKCK and its relocalization after SPP challenge of C2C12
myoblasts do not exclude that a direct interaction between the
two proteins may take place. Alternatively, PKCK could in-
directly regulate RhoA activation status and its cellular dis-
tribution, for instance through the phosphorylation of Rho-
speci¢c nucleotide exchange factor. The identi¢cation of
PKCK as an upstream regulator of RhoA translocation in-
duced by SPP, however, does not necessarily imply that
PKC activation can independently activate RhoA, because
other Edg receptor-mediated signals, in addition to PKC ac-
tivation, may be needed to relocalize RhoA.
This study represents the ¢rst evidence that SPP signaling
to RhoA speci¢cally involves PKCK activation. This ¢nding
may be physiologically relevant in view of the key role played
by PKC and RhoA in the control of crucial biological pro-
cesses. Consistently, RhoA has been reported to participate to
stimulation of SPP-induced phospholipase D activity [23] and
similarly PKC is known to act as a positive regulator in the
SPP-mediated enzyme activation [14,24]. Another possible
common target of the action of RhoA and PKC could be
represented by immediate early genes which are induced
through the activation of serum response elements [25]. There-
fore, it will be worth investigating whether such a functional
relationship between RhoA and PKC has a role in SPP-medi-
ated regulation of downstream e¡ectors.
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